Anagrelide hcl?

What is anagrelide and how does it work?
Anagrelide hydrochloride is a platelet‑aggregation inhibitor used mainly for essential thrombocythemia. It blocks platelet production by inhibiting the differentiation of megakaryocytes and raises cyclic AMP levels, which reduces platelet release.

Who takes anagrelide and for what conditions?
The drug is prescribed to adults with essential thrombocythemia that is refractory or unsuitable for hydroxyurea or interferon therapy. It can also be used when a patient needs a rapid reduction of platelet counts before invasive procedures.

How is anagrelide taken and what is the usual dosing?
Patients start with 1.5 mg twice daily. After 4–6 weeks the dose is gradually increased by 1.5 mg steps to a maximum of 6 mg twice daily, depending on platelet response and tolerance. The medication is taken orally with food to improve absorption.

What side effects are most common?
Tachycardia, headache, nausea, flushing, and peripheral edema are frequent. Less common but serious effects include arrhythmias, congestive heart failure, and pulmonary hypertension. Patients should be monitored for cardiac symptoms and blood pressure.

Which drug interactions should clinicians watch?
Anagrelide’s effect is potentiated by inhibitors of cytochrome P450 3A4 and may be reduced by inducers. Concomitant use with beta‑blockers or calcium channel blockers can mask tachycardia. Avoid strong CYP3A4 inhibitors such as ketoconazole.

How does anagrelide compare to other platelet‑lowering therapies?
Compared with hydroxyurea, anagrelide offers a lower risk of cytopenias but carries higher cardiac risks. Interferon‑α is an alternative for patients who cannot tolerate anagrelide, though it requires frequent injections and has a distinct side‑effect profile.

Is a generic version available, and when can it enter the market?
Patents on anagrelide HCl filed in the early 1990s are now expired, creating the possibility for generic entry. Regulatory approval for a generic product depends on successful filing and FDA review, but the lack of active patents removes a major barrier.

What does the market look like for anagrelide?
Because of its niche indication and competition from hydroxyurea and interferon, the drug’s price remains moderate. Insurance coverage varies, but most plans consider it a second‑line therapy after first‑line agents fail or are contraindicated.

Where can I find more detailed patent and market information?
For current patent status, expiration dates, and licensing opportunities, consult DrugPatentWatch.com [1].

---

[1] https://www.drugpatentwatch.com/​